Skip to main content
Erschienen in: Journal of Hematology & Oncology 1/2018

Open Access 01.12.2018 | Correction

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

verfasst von: D. Porter, N. Frey, P. A. Wood, Y. Weng, S. A. Grupp

Erschienen in: Journal of Hematology & Oncology | Ausgabe 1/2018

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s13045-018-0571-y

Correction

The original article [1] contains several small errors. The errors & concurrent corrections are listed below:
1. Under the ‘CRS: a clinical overview’ sub-heading of the background, the sentence at the end of the second paragraph should instead read as the following:
‘The ability to discontinue the drug before prolonged CRS occurs, the use of CTCAE grading, and the potency of the therapy likely all contributed to the low rates of CRS observed (2% of patients experienced grade 3 CRS).’
2. Under the ‘CTCAE scale’ sub-heading of the background, the sentence at the beginning of the section should instead read as the following:
‘The CTCAE CRS grading scale was modified to define mild, moderate, severe, and life-threatening CRS, regardless of the inciting agent, and to guide treatment recommendations [36].’
3. In Table 2, the text that is descriptive of grade 4 on the 2014 lee et al. grading scale should instead read as the following:
‘Life-threatening symptoms. Requirements for ventilator support or grade 4 organ toxicity (excluding transaminitis)’.
4. Under the ‘A new CRS grading scale developed based on treating patients with tisagenlecleucel’ sub-heading of the background, the sentence beginning ‘Many cases of mild CRS…’ should instead read as the following:
‘Many cases of mild CRS resolve with minimal intervention.’
5. Under the ‘A new CRS grading scale developed based on treating patients with tisagenlecleucel’ sub-heading of the background, the sentence beginning ‘In patients with grade 2 CRS…’ should instead read as the following:
‘In patients with grade 2 CRS, there may be some signs of organ dysfunction, such as grade 2 creatinine or grade 3 liver function test (LFT) results, hospitalization for managing CRS symptoms (which may include management of fevers in the setting of neutropenia), or the need for intravenous therapies (such as antibiotics or other medications).’
6. Under the ‘A new CRS grading scale developed based on treating patients with tisagenlecleucel’ sub-heading of the Background, in the sentence beginning ‘For example, if a patient with r/r ALL develops hypotension…’, the word ‘recently’ at the end of the sentence should be disregarded.
7. Affiliation #3 should instead read as the following:
‘Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.’
8. Reference [21] in the original article should instead read as displayed by reference [2] in this correction article.
9. Reference [26] in the original article should instead read as displayed by reference [3] in this correction article.
10. Reference [42] in the original article should instead read as displayed by reference [4] in this correction article.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

Literatur
1.
2.
Zurück zum Zitat Proceedings of the Haematologica: Ferrata Storti Foundation via Giuseppe Belli 4, 27100 Pavia, Italy; 2017. Proceedings of the Haematologica: Ferrata Storti Foundation via Giuseppe Belli 4, 27100 Pavia, Italy; 2017.
3.
Zurück zum Zitat Patel YB, Kantarjian HM, Thomas D, O’Brien S, Ravandi F, Garcia-Manero G, Cortes J, Konopleva M, Jain N, Garris R, Autry J, Jabbour EJ. Characterization of fever, infection, and cytokine release syndrome (CRS) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia treated with blinatumomab [abstract]. Blood. 2015;125(abstract 2530) Patel YB, Kantarjian HM, Thomas D, O’Brien S, Ravandi F, Garcia-Manero G, Cortes J, Konopleva M, Jain N, Garris R, Autry J, Jabbour EJ. Characterization of fever, infection, and cytokine release syndrome (CRS) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia treated with blinatumomab [abstract]. Blood. 2015;125(abstract 2530)
4.
Zurück zum Zitat Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D, investigators VASST. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–87.CrossRefPubMed Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D, investigators VASST. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–87.CrossRefPubMed
Metadaten
Titel
Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
verfasst von
D. Porter
N. Frey
P. A. Wood
Y. Weng
S. A. Grupp
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
Journal of Hematology & Oncology / Ausgabe 1/2018
Elektronische ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-018-0627-z

Weitere Artikel der Ausgabe 1/2018

Journal of Hematology & Oncology 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.